Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates
07:33pm, Tuesday, 09'th Aug 2022
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -241.18% and 129.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stoc
Emergent Biosolutions (EBS) Reports Q2 Loss, Misses Revenue Estimates
10:15pm, Monday, 01'st Aug 2022 Zacks Investment Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -236.51% and 16.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
02:01pm, Monday, 01'st Aug 2022 Zacks Investment Research
Avidity Biosciences, Inc. (RNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Fast-Growing Stocks to Buy Now
01:00pm, Sunday, 31'st Jul 2022 The Motley Fool
ShockWave, Vir, and BioCryst are all seeing skyrocketing sales this quarter.
3 Fast-Growing Stocks to Buy Now
09:00am, Sunday, 31'st Jul 2022
ShockWave, Vir, and BioCryst are all seeing skyrocketing sales this quarter.
2 Biotech Stocks That Could Help Make You a Fortune
10:15am, Saturday, 30'th Jul 2022 The Motley Fool
These companies have seen triple-digit revenue growth in recent years.
Analysts Estimate Vir Biotechnology, Inc. (VIR) to Report a Decline in Earnings: What to Look Out for
02:03pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance
04:47pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.
GSK Gears Up to Report Q2 Earnings: What's in the Cards?
02:59pm, Monday, 25'th Jul 2022 Zacks Investment Research
The newer respiratory and HIV drugs of GSK are likely to have driven second-quarter sales. The performance of Xevudy, GSK's monoclonal antibody for COVID-19, remains to be seen when the company report
3 Cheap Stocks To Buy Now
03:30pm, Tuesday, 12'th Jul 2022 The Motley Fool
COVID fighters and crypto brokers are super-cheap right now.
Immatics (IMTX) Stock Jumps 5.2%: Will It Continue to Soar?
02:47pm, Monday, 27'th Jun 2022 Zacks Investment Research
Immatics (IMTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
11:00am, Saturday, 25'th Jun 2022 GlobeNewswire Inc.
– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signal
Buy the Dip on These 3 Healthcare Stocks
03:25pm, Sunday, 19'th Jun 2022 The Motley Fool
Here's why our roundtable likes Vir Biotechnology, OrthoPediatrics, and Vertex Pharmaceuticals.
Buy the Dip on These 3 Healthcare Stocks
11:25am, Sunday, 19'th Jun 2022
Here's why our roundtable likes Vir Biotechnology, OrthoPediatrics, and Vertex Pharmaceuticals.
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
11:34am, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accep
